Stanford will rename campus spaces named for David Starr Jordan and relocate statue depicting Louis Agassiz
By Chris Peacock,
Stanford News
| 10. 07. 2020
Stanford will rename campus features named after David Starr Jordan and take actions to provide the public with a more complete view of his complex history, which includes not only his seminal leadership as the university’s founding president but also his parallel leadership in promoting eugenics.
The university will also relocate from the façade of Jordan Hall a statue of Jordan’s mentor, Louis Agassiz.
The decision follows a review conducted this summer by a committee of faculty, staff, students and alumni. The university’s Board of Trustees, acting on a recommendation by President Marc Tessier-Lavigne, approved these steps:
- Removing Jordan’s name from Jordan Hall, current home of the Department of Psychology; Jordan Quad and Jordan Modulars, near Panama Street and Campus Drive West; and Jordan Way in the Stanford Medical Center area;
- Relocating a statue of Agassiz from Jordan Hall to a location where it can be given appropriate context; and
- Developing an active effort to better explain the full range of Jordan’s legacy and contributions, beginning with an informational plaque in Jordan Hall and extending to additional efforts such as...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Gerry Smith, Bloomberg | 03.12.2024
When Celenise Mahmood first learned about two new gene therapies that could cure sickle cell disease, she felt a wave of relief.
Her 9-year-old son, Navid, has the inherited blood disorder. By age 5, he’d had over 30 life-saving blood...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...